Principal Financial Group Inc Keros Therapeutics, Inc. Transaction History

Principal Financial Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$44.58 - $66.89 $80,154 - $120,268	-1,798 Reduced 25.46%	5,265 $240,000
Q1 2024 Apr 29, 2024	BUY	$41.26 - $70.48 $23,683 - $40,455	574 Added 8.85%	7,063 $467,000
Q4 2023 Feb 07, 2024	SELL	$27.12 - $41.05 $623 - $944	-23 Reduced 0.35%	6,489 $258,000
Q3 2023 Nov 02, 2023	SELL	$31.57 - $43.02 $3,157 - $4,302	-100 Reduced 1.51%	6,512 $207,000
Q2 2023 Aug 07, 2023	BUY	$37.26 - $51.01 $27,386 - $37,492	735 Added 12.51%	6,612 $265,000
Q1 2023 May 09, 2023	SELL	$41.44 - $59.32 $16,576 - $23,728	-400 Reduced 6.37%	5,877 $250,000
Q4 2022 Feb 09, 2023	BUY	$39.45 - $51.77 $247,627 - $324,960	6,277 New	6,277 $301,000
Q1 2021 May 10, 2021	SELL	$54.0 - $75.28 $169,560 - $236,379	-3,140 Closed	0 $0
Q4 2020 Feb 08, 2021	BUY	$36.0 - $82.74 $113,040 - $259,803	3,140 New	3,140 $221,000

174

30.3M

76.8K

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.71B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.